In yesterday’s Wall Street session, BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) shares traded at $2.77, up 0.73% from the previous session.
BVXV stock price is now -57.58% away from the 50-day moving average and -72.92% away from the 200-day moving average. The market capitalization of the company currently stands at $5.35M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
.
A total of 27.75% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BVXV stock. A new stake in BiondVax Pharmaceuticals Ltd. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $3,000. In total, there are 17 active investors with 1.10% ownership of the company’s stock.
Monday morning saw BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) opened at $2.9700. During the past 12 months, BiondVax Pharmaceuticals Ltd. has had a low of $2.37 and a high of $22.90. As of last week, the company has a debt-to-equity ratio of 6.74, a current ratio of 5.80, and a quick ratio of 5.80. The fifty day moving average price for BVXV is $6.5301 and a two-hundred day moving average price translates $10.2307 for the stock.
The latest earnings results from BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.02, beating analysts’ expectations of -$0.1 by 0.08. This compares to -$1.96 EPS in the same period last year. The company reported revenue of $-1.14 million for the quarter, compared to $2.55 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -144.7 percent.
BiondVax Pharmaceuticals Ltd.(BVXV) Company Profile
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
